Commercial Stage Biotech Stocks
Biopharmaceutical entities in this phase have transitioned from pure R&D organizations into commercial enterprises focused on the manufacture, marketing, and distribution of FDA-approved therapies. Revenue models shift from speculative milestone payments to product sales and royalty streams, requiring heavy investment in specialized sales forces and market access infrastructure.
As of Oct 23, 2026, Commercial Stage Biotech has 128 US-listed companies worth $1.2T combined. The median member moved +1.2% over the past week; GMAB led among the 25 largest at +18.4% and CORT trailed at -22.1%.
Companies in Commercial Stage Biotech
- AMGN – Amgen Inc, $237B
- VRTX – Vertex Pharmaceuticals Inc, $136B
- MRNA – Moderna Inc, $79.9B
- TAK – Takeda Pharmaceutical Co Ltd ADR, $64.7B
- ARGX – argenx NV ADR, $54.9B
- ONC – BeiGene, Ltd., $43B
- RVMD – Revolution Medicines Inc, $40.2B
- BIIB – Biogen Inc, $37B
- ALNY – Alnylam Pharmaceuticals Inc, $30B
- ROIV – Roivant Sciences Ltd, $27.1B
- GMAB – Genmab AS, $26.9B
- UTHR – United Therapeutics Corporation, $25.1B
- INCY – Incyte Corporation, $23.7B
- BNTX – BioNTech SE, $22.9B
- GH – Guardant Health Inc, $21.9B
- INSM – Insmed Inc, $20.4B
- EXEL – Exelixis Inc, $16.2B
- ASND – Ascendis Pharma AS, $16B
- NBIX – Neurocrine Biosciences Inc, $14.6B
- HALO – Halozyme Therapeutics Inc, $14.1B
- BBIO – BridgeBio Pharma Inc, $13.4B
- CORT – Corcept Therapeutics Incorporated, $11.6B
- BMRN – Biomarin Pharmaceutical Inc, $10.8B
- MDGL – Madrigal Pharmaceuticals Inc, $10B
- KRYS – Krystal Biotech Inc, $9.6B
- IBRX – Immunitybio Inc, $8.8B
- CYTK – Cytokinetics Inc, $8.5B
- ARWR – Arrowhead Pharmaceuticals Inc, $8.2B
- TGTX – TG Therapeutics Inc, $8.1B
- AXSM – Axsome Therapeutics Inc, $7.6B
- ALKS – Alkermes Plc, $7.4B
- IONS – Ionis Pharmaceuticals Inc, $7.3B
- IOVA – Iovance Biotherapeutics Inc, $6.4B
- KNSA – Kiniksa Pharmaceuticals Ltd, $6.3B
- RYTM – Rhythm Pharmaceuticals Inc, $6.3B
- MIRM – Mirum Pharmaceuticals Inc, $5.3B
- PTCT – PTC Therapeutics Inc, $5.3B
- TVTX – Travere Therapeutics Inc, $4.9B
- CRSP – Crispr Therapeutics AG, $4.8B
- ARQT – Arcutis Biotherapeutics Inc, $4B
- ADPT – Adaptive Biotechnologies Corp, $3.9B
- TLX – Telix Pharmaceuticals Limited, $3.8B
- LEGN – Legend Biotech Corp, $3.7B
- LQDA – Liquidia Technologies Inc, $3.6B
- ACAD – ACADIA Pharmaceuticals Inc, $3.5B
- TARS – Tarsus Pharmaceuticals Inc, $3.3B
- ZLAB – Zai Lab Ltd, $2.7B
- HCM – HUTCHMED DRC, $2.5B
- SUPN – Supernus Pharmaceuticals Inc, $2.4B
- PGEN – Precigen Inc, $2.3B
- AGIO – Agios Pharm, $2.2B
- AUPH – Aurinia Pharmaceuticals Inc, $2.2B
- HRMY – Harmony Biosciences Holdings, $2.1B
- VCEL – Vericel Corp Ord, $2.1B
- XERS – Xeris Pharmaceuticals Inc, $2B
- BCRX – BioCryst Pharmaceuticals Inc, $2B
- ALVO – Alvotech, $1.9B
- SRPT – Sarepta Therapeutics Inc, $1.8B
- NVCR – Novocure Ltd, $1.8B
- MESO – Mesoblast Ltd, $1.7B
- NUVB – Nuvation Bio Inc, $1.7B
- URGN – UroGen Pharma Ltd, $1.7B
- OCUL – Ocular Therapeutix Inc, $1.7B
- RARE – Ultragenyx, $1.6B
- IMCR – Immunocore Holdings Ltd, $1.5B
- SNDX – Syndax Pharmaceuticals Inc, $1.2B
- KURA – Kura Oncology Inc, $944M
- RIGL – Rigel Pharmaceuticals Inc, $881M
- ARDX – Ardelyx Inc, $842M
- LXRX – Lexicon Pharmaceuticals Inc, $783M
- VSTM – Verastem Inc, $781M
- GERN – Geron Corporation, $771M
- GYRE – Gyre Therapeutics Inc., $717M
- COLL – Collegium Pharmaceutical Inc, $701M
- PHAR – Pharming Group NV, $690M
- ZVRA – Zevra Therapeutics Inc., $676M
- OABI – OmniAb Inc., $663M
- IRWD – Ironwood Pharmaceuticals Inc, $620M
- CRMD – CorMedix Inc, $576M
- PHAT – Phathom Pharmaceuticals Inc, $551M
- DCTH – Delcath Systems Inc, $534M
- VALN – Valneva SE ADR, $527M
- PBYI – Puma Biotechnology Inc, $506M
- AUTL – Autolus Therapeutics Ltd, $482M
- SPRY – ARS Pharmaceuticals, Inc, $427M
- FENC – Fennec Pharmaceuticals Inc, $358M
- BNTC – Benitec Biopharma Ltd ADR, $335M
- ARCT – Arcturus Therapeutics Holdings Inc, $308M
- VNDA – Vanda Pharmaceuticals Inc, $273M
- CUVL – Clinuvel Pharmaceuticals Limited American Depositary Shares, $262M
- AMRN – Amarin Corporation PLC, $261M
- ABEO – Abeona Therapeutics Inc, $252M
- XFOR – X4 Pharmaceuticals Inc, $243M
- SIGA – SIGA Technologies Inc, $234M
- SLGL – Sol Gel Technologies Ltd, $227M
- ADCT – ADC Therapeutics SA, $217M
- PLX – Protalix Biotherapeutics Inc, $210M
- ACOG – Alpha Cognition Inc, $192M
- IVVD – Invivyd Inc., $182M
- AKBA – Akebia Ther, $171M
- DERM – Journey Medical Corp, $160M
- MDWD – Mediwound Ltd, $158M
- CHRS – Coherus BioSciences Inc, $156M
- OTLK – OUTLOOK THERAPEUTICS INC, $127M
- HUMA – Humacyte Inc, $119M
- LENZ – LENZ Therapeutics Inc, $102M
- MIST – Milestone Pharmaceuticals Inc, $98.2M
- PTHS – Pelthos Therapeutics Inc., $85M
- CTOR – Citius Oncology, Inc., $81.2M
- FBIO – Fortress Biotech Inc, $67.7M
- HRTX – Heron Therapeuti, $58.1M
- PRPO – Precipio Inc, $38.9M
- SCYX – Scynexis Inc, $37.7M
- ELUT – Elutia Inc., $34.2M
- KYNB – Kyntra Bio, Inc., $23.8M
- SCLX – Scilex Holding Company, $19.9M
- CUPR – Cuprina Holdings (Cayman) Limited Class A Ordinary Shares, $16.9M
- CTXR – Citius Pharmaceuticals Inc, $14.6M
- DARE – Dare Bioscience Inc, $13.5M
- BFRI – Biofrontera Inc, $12M
- BLRX – BioLineRx Ltd, $11.7M
- KPTI – Karyopharm Therapeutics Inc, $8.8M
- BIAF – bioAffinity Technologies, Inc., $4.8M
- SCNX – Scienture Holdings, Inc., $4.5M
- ONCO – Onconetix Inc, $2.5M
- BTAI – BioXcel Therapeutics Inc, $2.3M
- EVFM – Evofem Biosciences Inc, $980,722
- XAGE – Longevity Health Holdings, Inc., $277,235